Study Population
We queried ADR reports for a subset of a broad “men’s health” data
consisting of drugs as follows (according to WHODrug): Phospho
Diesterase Inhibitors, PDE5i (Sildenafil, Tadalafil, Vardenafil,
Avanafil), Prostaglandin Agonist: Alprostadil, Alpha-1 Antagonists
(Phentolamine, Tamsulosin, Terazosin, Alfuzosin, Silodosin), Anti
Diuretic Hormone analog (Desmopressin), Anti-Cholinergics (Oxybutynin,
Tolterodine Darifenacin, Solifenacin, Trospium, Festerodine), Beta-3
Agonist (Mirabegron, Vibegron). We searched for the ADR reports for
sildenafil, tadalafil, avanafil, vardenafil, papaverine, and alprostadil
in men and extracted the ones in which the corresponding drug was listed
as “suspect” or “interacting” before September
29th, 2021. Next, the reports with an uncommon or
unknown route of administration for ED treatment purposes were excluded:
all routes other than oral and intracavernousal for PDE5is and
alprostadil/papaverine, respectively. Of note, we included all men
taking these medications regardless of indication.